
|Articles|September 1, 2004
Serum BPSA may distinguish BPH from prostate Ca
San Francisco--Serum BPSA, an antigen enriched in the nodular transition zone tissue in BPH, appears to be a better predictor of clinically significant prostate enlargement than PSA or free PSA. This finding and complementary data, by researchers from the Scott Department of Urology, Baylor College of Medicine, Houston, lay the groundwork for further study that will determine the antigen's potential to distinguish between BPH and prostate cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Study launches of MRI plus PSMA-PET imaging for prostate cancer detection
2
CREST and POTOMAC: Redefining immunotherapy’s role in NMIBC
3
Practical uses of AI across the urologic care continuum
4
New Data Influencing your Treatment Decisions in mCSPC
5



















